Support FLC research this GivingTuesday

Each year on GivingTuesday, millions of people come together to celebrate generosity, share kindness and donate to causes they care about. A celebration of all types of generosity, GivingTuesday inspires people around the world to give gifts of money, time, skills, advocacy, and more. Everyone has something to give and every act of generosity counts. …

Read more

FCF earns Platinum Seal

We’re excited to share that FCF has earned a 2022 Platinum Seal of Transparency with Candid. The Platinum Seal of Transparency is the highest level of recognition offered by Candid and GuideStar, the world’s largest source of nonprofit information. To receive the 2022 Platinum Seal, FCF shared important information with Candid that is included in …

Read more

… Spreading the word about rare cancers

Many thanks to Destiny and Bill Haggett, Chansen and the rest of their family for helping to spread the word about the importance of rare disease advocacy on this Rare Cancer Day. Destiny was instrumental in getting Coral Springs and Coconut Creek, Florida to proclaim Sept. 30 as “Rare Cancer Awareness Day” in those cities. …

Read more

FCF staffing changes announced

John Hopper, who has successfully led FCF for the past eight years, has informed us that he would like to step back and focus his efforts on special initiatives, including fund advancement. John’s new focus as President Emeritus will be critically important to accelerating FCF’s research efforts by providing additional funding for research. We are …

Read more

A Rare Cancer Day message

The Fibrolamellar Cancer Foundation (FCF) kicks off Rare Cancer Day with a special video created by the fibrolamellar community …

Read more

Collaborative FLC research effort funded by National Cancer Institute

FCF is pleased to announce that two of its research partners – Mark Yarchoan, MD of the Johns Hopkins Kimmel Cancer Center and Paul Thomas, PhD of St. Jude Children’s Medical Center have received significant funding from the National Cancer Institute (NCI) for a collaborative fibrolamellar research project. Their initiative “Neoantigen-specific T cell responses for …

Read more